Healthcare Economics & Outcomes Research
At CSI, we’re on a mission to improve healthcare access and care for coronary artery disease (CAD) and peripheral artery disease (PAD). We’re on a mission to educate patients and physicians. We’re on a mission to improve access and patient outcomes and to deliver value. We collaborate with providers and policy makers to help ensure fair and accurate reimbursement for treatment.
We support groundbreaking research as well as its subsequent publication and presentation to the healthcare community. CSI leaders present at the International Society for Pharmacoeonomics and Outcomes Research (ISPOR) each year.
CSI is a proud supporter of the CardioVascular Coalition, and we continually seek out like-minded industry groups to advance CAD and PAD treatment.
Improving PCI Outcomes for Patients with Complex CAD
At CSI, we’re dedicated to helping reduce severe arterial calcium and enable successful stent delivery to help optimize stent expansion and PCI outcomes. Much of the research surrounding endovascular treatments for CAD exclude patients with severely calcified lesions.
At CSI, we’re focused on developing solutions for this difficult-to-treat population and studying the effectiveness and patient outcomes using orbital atherectomy technology.
Leading the Way for Racial Healthcare Equity in PAD
Peripheral artery disease (PAD) affects up to 18 million people in the US, according to estimates.22 And the numbers will continue to increase:
- PAD primary or secondary visits expected to top 1.7 million by 202027
- PAD and PAD-associated leg amputations visits expected to reach 70,000 by 202027
Some studies suggest that African-Americans may not feel the symptoms as early as Caucasians, therefore they do not seek treatment as early.34
CSI seeks to identify racial and ethnic disparities in PAD treatment through our dedicated research and legislative advocacy efforts.
African-Americans & Hispanics are 2X as likely to be amputated as Caucasians29
Analysis of amputation rates for the treatment of patients with a primary diagnosis of PAD, using the Healthcare Cost and Utilization Project (HCUP) inpatient database from 2006-2013.
CSI’s Dedication to Research
Clinical research supports our goal of informing health policy. We seek to understand the disease state and patient factors. We find ways to help save limbs and advocate for better access to care in the African-American, Hispanic and Native American communities.
Important findings of our recent research determine that:
- African-Americans are twice as likely and Hispanics are 50% more likely to be amputated than Caucasians as a result of advanced PAD28
- Results suggest African-Americans and Hispanics have less access to care because they are being admitted when sicker and more likely on an emergent basis28
- Caucasians were generally older (average age 70.3 vs. 67.8), wealthier, had less severe diseases and a lower mortality risk than African-Americans or Hispanics28
- African-Americans have an average number of 1,503 PAD-related amputations per year29
- The amputation rate per minority translates into aggregate healthcare costs of up to $1.12 billion29
2011
• Introduced New Reimbursement/Procedure Codes
2012
• Promoted International Efforts
2013
• Supported OEIS
• Supported Coding to Increase Medicare Payments
2014
• Helped Create Cardiovascular Coalition
• Proposed CLI/Amputation Payment Model
2015
• Helped Form CLI Medical Society
• Met With CMS
• Presented to (MEDCAC)
2016
• Worked with CMS on Mandated Screening Strategy
2017
• Worked with Congress on PAD Medicare Coverage Legislation
A CardioVascular Coalition Charter Member
The CardioVascular Coalition (CVC) understands that PAD is a leading and preventable cause of death in the US. CSI – along with national physician, provider and advocacy organizations – created the CVC to improve the awareness of and prevention of PAD.
As a coalition, we will secure patient access to high-quality, cost-effective interventional treatment for PAD. To help achieve this goal, the CVC currently operates 211 CardioVascular Centers in 31 states.
States with CardioVascular Centers
Supporting Value-based Technology
The CSI team is committed to assisting healthcare policymakers and healthcare providers in evaluating the economic impact of utilizing orbital atherectomy technology. Our team can provide the background and resources you need to evaluate procedures.
Economic Evidence
Analysis of cost-effectiveness of treatment with orbital atherectomy
Professional Education
CSIQ® is the official professional education program of Cardiovascular Systems, Inc. Our goal is for you to use this information to better understand the prevalence of arterial calcium and how to treat it using our Orbital Atherectomy Systems. From group courses taught by leading orbital atherectomy experts to personalized, one-on-one proctorships, CSIQ® demonstrates the value and procedural efficiency of our Orbital Atherectomy Systems. Clinical data that underscore the safety, efficacy and long-term durability of the devices is also provided.
